PET-CT features predict progression from subclinical TB to symptomatic TB disease, but interferon gamma release assays do not - Amsterdam 2025

Tuberculosis and non-tuberculous mycobacterial diseases: challenges of diagnostics and management

Chair(s): Olha Konstantynovska, Christoph Lange

Session type: Oral presentation

PET-CT features predict progression from subclinical TB to symptomatic TB disease, but interferon gamma release assays do not

Jane Shaw

EVENTS HOME

Previous presentation

Next presentation

Session content

Late Breaking Abstract - Ibuprofen and acetylsalycilic acid as adjunctive to anti-tuberculosis treatment: Phase II clinical trial

Cristina Vilaplana Massaguer

Replay

Poster

Abstract

Slides

Diagnosis and treatment of articular TB: An East London case series

Bruno Tanushi

Replay

Poster

Abstract

Slides

One-month rifapentine plus isoniazid for latent tuberculosis: less is more?

Joana Filipe Marques Simões

Replay

Poster

Abstract

Slides

Tuberculosis during JAK inhibitors therapy, a WHO pharmacovigilance database study

Thomas Maitre

Replay

Poster

Abstract

Slides

Impact of climate and urbanization on NTM infections: an Italian nationwide case-control study

Paola Faverio

Replay

Poster

Abstract

Slides

Tigecycline dry powder inhalation to cure Mycobacterium abscessus lung disease: a dose finding study

Jakko Van Ingen

Replay

Poster

Abstract

Slides

PET-CT features predict progression from subclinical TB to symptomatic TB disease, but interferon gamma release assays do not

Jane Shaw

Replay

Poster

Abstract

Slides

Persistent respiratory symptoms and increased reactance among successfully treated Australian TB survivors compared to healthy controls.

Anthony Byrne

Replay

Poster

Abstract

Slides

Measuring post-tuberculosis lung disease treatment efficacy: The need for standardised outcomes in clinical research

Maria Puthoor

Replay

Poster

Abstract

Slides

Nanopore targeted sequencing for the detection of drug-resistant tuberculosis compared to standard of care drug susceptibility testing in Kyrgyzstan

Edine Tiemersma

Replay

Poster

Abstract

Slides

Discussion and Q&A

Replay

CDN Connection Issue

The ERS Congress 2025, Amsterdam

#{title}